300233 金城医药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.0754.7727.8083.161-13.030
总资产报酬率 ROA (%)2.6222.9764.9252.102-9.230
投入资产回报率 ROIC (%)3.2473.7736.1802.558-10.935

边际利润分析
销售毛利率 (%)40.13243.72746.22352.61658.120
营业利润率 (%)7.7636.38310.0916.693-14.005
息税前利润/营业总收入 (%)7.8926.66110.2887.078-13.427
净利润/营业总收入 (%)6.4455.4638.1553.922-16.229

收益指标分析
经营活动净收益/利润总额(%)92.470108.534107.602111.833-77.231
价值变动净收益/利润总额(%)-0.9290.2260.8565.785-0.480
营业外收支净额/利润总额(%)0.851-0.196-2.258-6.8682.484

偿债能力分析
流动比率 (X)1.6511.4801.3571.5101.934
速动比率 (X)1.2031.1671.0161.2341.687
资产负债率 (%)32.86836.08837.19234.8000.307
带息债务/全部投入资本 (%)15.77716.79116.82615.68014.386
股东权益/带息债务 (%)508.298471.687469.060506.267573.681
股东权益/负债合计 (%)200.862173.962166.483184.911224.292
利息保障倍数 (X)127.40522.93024.5288.681-14.373

营运能力分析
应收账款周转天数 (天)58.45960.46460.51374.01885.594
存货周转天数 (天)98.72797.67892.66581.75077.773